Clinical Trial

Optimization of Perioperative Antibiotic Prophylaxis in Patients Allergic to Beta-lactams in the Orthopedic Surgery and Trauma Departments

Study acronym: ORTHO-PEN
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 15, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
When surgery is required, a consultation with an anesthesiologist is mandatory. This preoperative consultation allows for the selection of the appropriate antibiotic prophylaxis tailored to the patient and the type of procedure. The French Society of Anesthesiology and Intensive Care (SFAR) has published recommendations on antibiotic prophylaxis for different types of surgery. During this consultation, several topics are addressed, including drug allergies. This topic plays a central role in the choice of antibiotic prophylaxis. Ten percent of the population is labeled as allergic to beta-lactams, but only 1% actually are. Diagnosis is difficult and requires specialized teams. In response to the significant increase in patients labeled as allergic, and consequently the rise in requests to specialists, a scoring system has been developed for use by all physicians: the PEN FAST score. This score stratifies the risk of a true penicillin allergy and guides the selection of delabeling strategies. The test aims to eliminate the need for skin prick tests and allows for the direct reintroduction of the drug when the score is below 3. It is based on five questions. Each question is assigned a point value, which is used to calculate a score and thus an estimated risk. The primary objective of this study is to improve the management of patients allergic to beta-lactams in orthopedic and trauma surgery by ensuring optimal and appropriate intraoperative antibiotic prophylaxis.
Trial Details
NCT Number NCT07342647
Lead Sponsor University Hospital, Strasbourg, France
Conditions Beta Lactam Adverse Reaction
Enrollment 50 participants
Start Date 2025-07-11
Primary Completion 2026-07 (estimated)
Study Completion 2026-07-11 (estimated)
Updated on ClinicalTrials.gov 2026-01-15